nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—EPHB2—prostate cancer	0.106	0.259	CbGaD
Dasatinib—BMPR1B—prostate cancer	0.0941	0.23	CbGaD
Dasatinib—BTK—Mitoxantrone—prostate cancer	0.0661	0.229	CbGbCtD
Dasatinib—JAK2—prostate cancer	0.046	0.113	CbGaD
Dasatinib—ERBB3—prostate cancer	0.0432	0.106	CbGaD
Dasatinib—PDGFRB—prostate cancer	0.0358	0.0875	CbGaD
Dasatinib—SRC—prostate cancer	0.0288	0.0706	CbGaD
Dasatinib—CYP1B1—Flutamide—prostate cancer	0.0243	0.0843	CbGbCtD
Dasatinib—CYP1B1—prostate cancer	0.0205	0.0503	CbGaD
Dasatinib—CYP1B1—Estrone—prostate cancer	0.0176	0.0609	CbGbCtD
Dasatinib—CYP3A5—prostate cancer	0.0164	0.04	CbGaD
Dasatinib—CYP1A1—prostate cancer	0.0111	0.0271	CbGaD
Dasatinib—CYP1A1—Flutamide—prostate cancer	0.0107	0.037	CbGbCtD
Dasatinib—CYP1B1—Mitoxantrone—prostate cancer	0.0105	0.0362	CbGbCtD
Dasatinib—CYP1B1—Estradiol—prostate cancer	0.0101	0.035	CbGbCtD
Dasatinib—ABCG2—Cabazitaxel—prostate cancer	0.00856	0.0296	CbGbCtD
Dasatinib—ABCG2—Estrone—prostate cancer	0.00837	0.029	CbGbCtD
Dasatinib—CYP1A1—Estrone—prostate cancer	0.00772	0.0267	CbGbCtD
Dasatinib—CYP3A4—prostate cancer	0.00708	0.0173	CbGaD
Dasatinib—CYP3A5—Flutamide—prostate cancer	0.00641	0.0222	CbGbCtD
Dasatinib—CYP1B1—Docetaxel—prostate cancer	0.00604	0.0209	CbGbCtD
Dasatinib—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.00574	0.0199	CbGbCtD
Dasatinib—ABCG2—Conjugated Estrogens—prostate cancer	0.00547	0.0189	CbGbCtD
Dasatinib—ABCG2—Mitoxantrone—prostate cancer	0.00498	0.0172	CbGbCtD
Dasatinib—ABCG2—Estradiol—prostate cancer	0.00481	0.0166	CbGbCtD
Dasatinib—CYP1A2—Flutamide—prostate cancer	0.00477	0.0165	CbGbCtD
Dasatinib—CYP3A5—Cabazitaxel—prostate cancer	0.00474	0.0164	CbGbCtD
Dasatinib—ABCB1—Estramustine—prostate cancer	0.00468	0.0162	CbGbCtD
Dasatinib—CYP3A5—Estrone—prostate cancer	0.00464	0.016	CbGbCtD
Dasatinib—CYP1B1—Doxorubicin—prostate cancer	0.0045	0.0156	CbGbCtD
Dasatinib—CYP1A1—Estradiol—prostate cancer	0.00444	0.0154	CbGbCtD
Dasatinib—CYP1A2—Estrone—prostate cancer	0.00345	0.0119	CbGbCtD
Dasatinib—ABCG2—Etoposide—prostate cancer	0.00314	0.0109	CbGbCtD
Dasatinib—ABCB1—Cabazitaxel—prostate cancer	0.00309	0.0107	CbGbCtD
Dasatinib—CYP3A4—Bicalutamide—prostate cancer	0.00302	0.0104	CbGbCtD
Dasatinib—ABCB1—Estrone—prostate cancer	0.00302	0.0104	CbGbCtD
Dasatinib—ABCG2—Docetaxel—prostate cancer	0.00287	0.00994	CbGbCtD
Dasatinib—CYP3A4—Estramustine—prostate cancer	0.00281	0.00971	CbGbCtD
Dasatinib—ABCB1—Ethinyl Estradiol—prostate cancer	0.00269	0.00931	CbGbCtD
Dasatinib—CYP3A5—Estradiol—prostate cancer	0.00266	0.00921	CbGbCtD
Dasatinib—CYP3A4—Flutamide—prostate cancer	0.0025	0.00865	CbGbCtD
Dasatinib—CYP3A4—Abiraterone—prostate cancer	0.0025	0.00865	CbGbCtD
Dasatinib—CYP1A2—Conjugated Estrogens—prostate cancer	0.00226	0.00781	CbGbCtD
Dasatinib—ABCG2—Doxorubicin—prostate cancer	0.00214	0.00741	CbGbCtD
Dasatinib—CYP1A2—Estradiol—prostate cancer	0.00198	0.00686	CbGbCtD
Dasatinib—ABCB1—Conjugated Estrogens—prostate cancer	0.00197	0.00683	CbGbCtD
Dasatinib—CYP3A4—Cabazitaxel—prostate cancer	0.00185	0.0064	CbGbCtD
Dasatinib—CYP3A4—Estrone—prostate cancer	0.00181	0.00626	CbGbCtD
Dasatinib—ABCB1—Mitoxantrone—prostate cancer	0.00179	0.00621	CbGbCtD
Dasatinib—CYP3A5—Etoposide—prostate cancer	0.00174	0.00602	CbGbCtD
Dasatinib—ABCB1—Estradiol—prostate cancer	0.00173	0.006	CbGbCtD
Dasatinib—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00161	0.00558	CbGbCtD
Dasatinib—CYP3A5—Docetaxel—prostate cancer	0.00159	0.0055	CbGbCtD
Dasatinib—ABCB1—Prednisone—prostate cancer	0.00149	0.00516	CbGbCtD
Dasatinib—CYP1A2—Etoposide—prostate cancer	0.00129	0.00448	CbGbCtD
Dasatinib—CYP3A4—Conjugated Estrogens—prostate cancer	0.00118	0.00409	CbGbCtD
Dasatinib—ABCB1—Etoposide—prostate cancer	0.00113	0.00392	CbGbCtD
Dasatinib—CYP3A4—Mitoxantrone—prostate cancer	0.00108	0.00372	CbGbCtD
Dasatinib—CYP3A4—Estradiol—prostate cancer	0.00104	0.00359	CbGbCtD
Dasatinib—ABCB1—Docetaxel—prostate cancer	0.00104	0.00358	CbGbCtD
Dasatinib—CYP3A4—Prednisone—prostate cancer	0.000893	0.00309	CbGbCtD
Dasatinib—ABCB1—Doxorubicin—prostate cancer	0.000772	0.00267	CbGbCtD
Dasatinib—CYP3A4—Etoposide—prostate cancer	0.000678	0.00235	CbGbCtD
Dasatinib—CYP3A4—Docetaxel—prostate cancer	0.00062	0.00215	CbGbCtD
Dasatinib—TNK2—prostate gland—prostate cancer	0.000485	0.00749	CbGeAlD
Dasatinib—BMX—urethra—prostate cancer	0.000467	0.0072	CbGeAlD
Dasatinib—TEC—testis—prostate cancer	0.000466	0.00719	CbGeAlD
Dasatinib—CYP3A4—Doxorubicin—prostate cancer	0.000462	0.0016	CbGbCtD
Dasatinib—TESK1—prostate gland—prostate cancer	0.000456	0.00704	CbGeAlD
Dasatinib—SRMS—renal system—prostate cancer	0.000454	0.00701	CbGeAlD
Dasatinib—STAT5B—epithelium—prostate cancer	0.000454	0.007	CbGeAlD
Dasatinib—STK36—prostate gland—prostate cancer	0.000449	0.00693	CbGeAlD
Dasatinib—EPHB3—prostate gland—prostate cancer	0.000449	0.00693	CbGeAlD
Dasatinib—PTK6—renal system—prostate cancer	0.000445	0.00687	CbGeAlD
Dasatinib—PTK6—urethra—prostate cancer	0.000437	0.00675	CbGeAlD
Dasatinib—ZAK—seminal vesicle—prostate cancer	0.000437	0.00674	CbGeAlD
Dasatinib—LIMK2—prostate gland—prostate cancer	0.000434	0.0067	CbGeAlD
Dasatinib—STAT5B—renal system—prostate cancer	0.000421	0.0065	CbGeAlD
Dasatinib—STK35—prostate gland—prostate cancer	0.000421	0.00649	CbGeAlD
Dasatinib—CSK—prostate gland—prostate cancer	0.000418	0.00645	CbGeAlD
Dasatinib—STAT5B—urethra—prostate cancer	0.000413	0.00638	CbGeAlD
Dasatinib—HCK—prostate gland—prostate cancer	0.000413	0.00637	CbGeAlD
Dasatinib—ABL2—prostate gland—prostate cancer	0.00041	0.00633	CbGeAlD
Dasatinib—RIPK2—prostate gland—prostate cancer	0.000388	0.00599	CbGeAlD
Dasatinib—TESK1—seminal vesicle—prostate cancer	0.000386	0.00596	CbGeAlD
Dasatinib—STK36—seminal vesicle—prostate cancer	0.00038	0.00586	CbGeAlD
Dasatinib—SIK1—prostate gland—prostate cancer	0.000379	0.00585	CbGeAlD
Dasatinib—EPHA4—prostate gland—prostate cancer	0.000375	0.00579	CbGeAlD
Dasatinib—ERBB3—prostate gland—prostate cancer	0.000371	0.00573	CbGeAlD
Dasatinib—PKMYT1—bone marrow—prostate cancer	0.000368	0.00568	CbGeAlD
Dasatinib—MAP3K2—prostate gland—prostate cancer	0.000368	0.00568	CbGeAlD
Dasatinib—EPHB1—testis—prostate cancer	0.000365	0.00564	CbGeAlD
Dasatinib—BMPR1B—epithelium—prostate cancer	0.000364	0.00561	CbGeAlD
Dasatinib—BMX—bone marrow—prostate cancer	0.000359	0.00554	CbGeAlD
Dasatinib—CSK—seminal vesicle—prostate cancer	0.000354	0.00546	CbGeAlD
Dasatinib—HCK—seminal vesicle—prostate cancer	0.000349	0.00539	CbGeAlD
Dasatinib—MAPK14—prostate gland—prostate cancer	0.000346	0.00534	CbGeAlD
Dasatinib—ZAK—urethra—prostate cancer	0.000346	0.00533	CbGeAlD
Dasatinib—FGR—prostate gland—prostate cancer	0.000344	0.00532	CbGeAlD
Dasatinib—LCK—prostate gland—prostate cancer	0.000344	0.00532	CbGeAlD
Dasatinib—SRMS—bone marrow—prostate cancer	0.000343	0.0053	CbGeAlD
Dasatinib—TXK—bone marrow—prostate cancer	0.00034	0.00525	CbGeAlD
Dasatinib—TEC—lymph node—prostate cancer	0.000337	0.00521	CbGeAlD
Dasatinib—CYP1A2—urine—prostate cancer	0.000334	0.00516	CbGeAlD
Dasatinib—FMO3—prostate gland—prostate cancer	0.000333	0.00513	CbGeAlD
Dasatinib—RIPK2—seminal vesicle—prostate cancer	0.000328	0.00506	CbGeAlD
Dasatinib—EPHB4—prostate gland—prostate cancer	0.000328	0.00506	CbGeAlD
Dasatinib—JAK2—prostate gland—prostate cancer	0.000325	0.00502	CbGeAlD
Dasatinib—EPHA2—prostate gland—prostate cancer	0.000322	0.00496	CbGeAlD
Dasatinib—FYN—prostate gland—prostate cancer	0.000321	0.00495	CbGeAlD
Dasatinib—STAT5B—bone marrow—prostate cancer	0.000318	0.00491	CbGeAlD
Dasatinib—FRK—testis—prostate cancer	0.000314	0.00485	CbGeAlD
Dasatinib—PKMYT1—testis—prostate cancer	0.000314	0.00485	CbGeAlD
Dasatinib—MAP3K3—prostate gland—prostate cancer	0.000314	0.00484	CbGeAlD
Dasatinib—MAP4K5—prostate gland—prostate cancer	0.000314	0.00484	CbGeAlD
Dasatinib—TESK1—renal system—prostate cancer	0.000311	0.0048	CbGeAlD
Dasatinib—TESK1—urethra—prostate cancer	0.000305	0.00471	CbGeAlD
Dasatinib—EPHB3—urethra—prostate cancer	0.000301	0.00464	CbGeAlD
Dasatinib—STK36—urethra—prostate cancer	0.000301	0.00464	CbGeAlD
Dasatinib—EPHB6—prostate gland—prostate cancer	0.0003	0.00463	CbGeAlD
Dasatinib—FGR—seminal vesicle—prostate cancer	0.000291	0.0045	CbGeAlD
Dasatinib—TXK—testis—prostate cancer	0.000291	0.00448	CbGeAlD
Dasatinib—YES1—prostate gland—prostate cancer	0.00029	0.00447	CbGeAlD
Dasatinib—EPHA8—testis—prostate cancer	0.000288	0.00444	CbGeAlD
Dasatinib—RIPK2—epithelium—prostate cancer	0.000285	0.0044	CbGeAlD
Dasatinib—CSK—renal system—prostate cancer	0.000285	0.0044	CbGeAlD
Dasatinib—PDGFRA—prostate gland—prostate cancer	0.000284	0.00439	CbGeAlD
Dasatinib—CSK—urethra—prostate cancer	0.00028	0.00432	CbGeAlD
Dasatinib—SRC—prostate gland—prostate cancer	0.000279	0.0043	CbGeAlD
Dasatinib—EPHB4—seminal vesicle—prostate cancer	0.000277	0.00428	CbGeAlD
Dasatinib—HCK—urethra—prostate cancer	0.000276	0.00426	CbGeAlD
Dasatinib—JAK2—seminal vesicle—prostate cancer	0.000275	0.00425	CbGeAlD
Dasatinib—ERBB3—epithelium—prostate cancer	0.000273	0.00421	CbGeAlD
Dasatinib—STAT5B—testis—prostate cancer	0.000272	0.0042	CbGeAlD
Dasatinib—EPHA2—seminal vesicle—prostate cancer	0.000272	0.0042	CbGeAlD
Dasatinib—FYN—seminal vesicle—prostate cancer	0.000272	0.00419	CbGeAlD
Dasatinib—MAP4K5—seminal vesicle—prostate cancer	0.000265	0.0041	CbGeAlD
Dasatinib—MAP3K3—seminal vesicle—prostate cancer	0.000265	0.0041	CbGeAlD
Dasatinib—EPHB1—lymph node—prostate cancer	0.000265	0.00409	CbGeAlD
Dasatinib—RIPK2—urethra—prostate cancer	0.00026	0.00401	CbGeAlD
Dasatinib—SIK1—renal system—prostate cancer	0.000258	0.00399	CbGeAlD
Dasatinib—MAP2K5—prostate gland—prostate cancer	0.000256	0.00396	CbGeAlD
Dasatinib—MAPK14—epithelium—prostate cancer	0.000254	0.00392	CbGeAlD
Dasatinib—BTK—bone marrow—prostate cancer	0.000254	0.00392	CbGeAlD
Dasatinib—SIK1—urethra—prostate cancer	0.000254	0.00391	CbGeAlD
Dasatinib—EPHB6—seminal vesicle—prostate cancer	0.000254	0.00391	CbGeAlD
Dasatinib—ERBB3—renal system—prostate cancer	0.000253	0.00391	CbGeAlD
Dasatinib—EPHA3—testis—prostate cancer	0.000251	0.00388	CbGeAlD
Dasatinib—EPHA4—urethra—prostate cancer	0.000251	0.00388	CbGeAlD
Dasatinib—CSF1R—prostate gland—prostate cancer	0.00025	0.00386	CbGeAlD
Dasatinib—YES1—seminal vesicle—prostate cancer	0.000245	0.00378	CbGeAlD
Dasatinib—SIK3—testis—prostate cancer	0.000245	0.00377	CbGeAlD
Dasatinib—CYP3A4—urine—prostate cancer	0.000242	0.00374	CbGeAlD
Dasatinib—EPHB4—epithelium—prostate cancer	0.000241	0.00372	CbGeAlD
Dasatinib—JAK2—epithelium—prostate cancer	0.000239	0.00369	CbGeAlD
Dasatinib—EPHA2—epithelium—prostate cancer	0.000236	0.00365	CbGeAlD
Dasatinib—MAPK14—renal system—prostate cancer	0.000236	0.00364	CbGeAlD
Dasatinib—FGR—urethra—prostate cancer	0.000231	0.00356	CbGeAlD
Dasatinib—LCK—urethra—prostate cancer	0.000231	0.00356	CbGeAlD
Dasatinib—TESK1—Estradiol—Estradiol valerate/Dienogest—prostate cancer	0.000229	0.113	CbGdCrCtD
Dasatinib—ZAK—testis—prostate cancer	0.000227	0.00351	CbGeAlD
Dasatinib—KIT—prostate gland—prostate cancer	0.000227	0.00351	CbGeAlD
Dasatinib—EPHB4—renal system—prostate cancer	0.000223	0.00345	CbGeAlD
Dasatinib—BMX—lymph node—prostate cancer	0.000223	0.00343	CbGeAlD
Dasatinib—PDGFRB—prostate gland—prostate cancer	0.000222	0.00343	CbGeAlD
Dasatinib—JAK2—renal system—prostate cancer	0.000222	0.00342	CbGeAlD
Dasatinib—BLK—lymph node—prostate cancer	0.00022	0.00339	CbGeAlD
Dasatinib—EPHB4—urethra—prostate cancer	0.000219	0.00339	CbGeAlD
Dasatinib—FYN—renal system—prostate cancer	0.000219	0.00338	CbGeAlD
Dasatinib—MAP3K19—testis—prostate cancer	0.000218	0.00336	CbGeAlD
Dasatinib—BMPR1B—testis—prostate cancer	0.000218	0.00336	CbGeAlD
Dasatinib—JAK2—urethra—prostate cancer	0.000218	0.00336	CbGeAlD
Dasatinib—BTK—testis—prostate cancer	0.000217	0.00335	CbGeAlD
Dasatinib—MAP2K5—seminal vesicle—prostate cancer	0.000217	0.00335	CbGeAlD
Dasatinib—CSK—bone marrow—prostate cancer	0.000215	0.00332	CbGeAlD
Dasatinib—EPHA2—urethra—prostate cancer	0.000215	0.00332	CbGeAlD
Dasatinib—FYN—urethra—prostate cancer	0.000215	0.00332	CbGeAlD
Dasatinib—TNK2—testis—prostate cancer	0.000214	0.0033	CbGeAlD
Dasatinib—HCK—bone marrow—prostate cancer	0.000213	0.00328	CbGeAlD
Dasatinib—CSF1R—seminal vesicle—prostate cancer	0.000212	0.00327	CbGeAlD
Dasatinib—TXK—lymph node—prostate cancer	0.000211	0.00325	CbGeAlD
Dasatinib—MAP4K5—urethra—prostate cancer	0.00021	0.00324	CbGeAlD
Dasatinib—MAP3K3—urethra—prostate cancer	0.00021	0.00324	CbGeAlD
Dasatinib—SRC—epithelium—prostate cancer	0.000205	0.00316	CbGeAlD
Dasatinib—PKMYT1—Fulvestrant—Estradiol—prostate cancer	0.000203	0.101	CbGdCrCtD
Dasatinib—TESK1—testis—prostate cancer	0.000201	0.0031	CbGeAlD
Dasatinib—EPHB6—urethra—prostate cancer	0.000201	0.0031	CbGeAlD
Dasatinib—RIPK2—bone marrow—prostate cancer	0.0002	0.00309	CbGeAlD
Dasatinib—STK36—testis—prostate cancer	0.000198	0.00305	CbGeAlD
Dasatinib—EPHB3—testis—prostate cancer	0.000198	0.00305	CbGeAlD
Dasatinib—ABL1—prostate gland—prostate cancer	0.000198	0.00305	CbGeAlD
Dasatinib—YES1—renal system—prostate cancer	0.000197	0.00305	CbGeAlD
Dasatinib—STAT5B—lymph node—prostate cancer	0.000197	0.00304	CbGeAlD
Dasatinib—SIK1—bone marrow—prostate cancer	0.000195	0.00301	CbGeAlD
Dasatinib—TESK1—Estradiol—Estramustine—prostate cancer	0.000194	0.0964	CbGdCrCtD
Dasatinib—YES1—urethra—prostate cancer	0.000194	0.00299	CbGeAlD
Dasatinib—PDGFRA—renal system—prostate cancer	0.000194	0.00299	CbGeAlD
Dasatinib—KIT—seminal vesicle—prostate cancer	0.000192	0.00297	CbGeAlD
Dasatinib—LIMK2—testis—prostate cancer	0.000191	0.00295	CbGeAlD
Dasatinib—SRC—renal system—prostate cancer	0.00019	0.00293	CbGeAlD
Dasatinib—MAP3K2—bone marrow—prostate cancer	0.00019	0.00293	CbGeAlD
Dasatinib—PDGFRB—seminal vesicle—prostate cancer	0.000188	0.0029	CbGeAlD
Dasatinib—STK35—testis—prostate cancer	0.000185	0.00286	CbGeAlD
Dasatinib—CSK—testis—prostate cancer	0.000184	0.00284	CbGeAlD
Dasatinib—EPHA3—lymph node—prostate cancer	0.000182	0.00281	CbGeAlD
Dasatinib—HCK—testis—prostate cancer	0.000182	0.00281	CbGeAlD
Dasatinib—ABL2—testis—prostate cancer	0.000181	0.00279	CbGeAlD
Dasatinib—MAPK14—bone marrow—prostate cancer	0.000178	0.00275	CbGeAlD
Dasatinib—FGR—bone marrow—prostate cancer	0.000177	0.00274	CbGeAlD
Dasatinib—LCK—bone marrow—prostate cancer	0.000177	0.00274	CbGeAlD
Dasatinib—SIK3—lymph node—prostate cancer	0.000177	0.00274	CbGeAlD
Dasatinib—MAP2K5—urethra—prostate cancer	0.000172	0.00265	CbGeAlD
Dasatinib—RIPK2—testis—prostate cancer	0.000171	0.00264	CbGeAlD
Dasatinib—EPHB4—bone marrow—prostate cancer	0.000169	0.00261	CbGeAlD
Dasatinib—JAK2—bone marrow—prostate cancer	0.000168	0.00259	CbGeAlD
Dasatinib—CSF1R—urethra—prostate cancer	0.000168	0.00259	CbGeAlD
Dasatinib—CYP1B1—prostate gland—prostate cancer	0.000168	0.00259	CbGeAlD
Dasatinib—ABL1—seminal vesicle—prostate cancer	0.000167	0.00258	CbGeAlD
Dasatinib—KIT—epithelium—prostate cancer	0.000167	0.00258	CbGeAlD
Dasatinib—SIK1—testis—prostate cancer	0.000167	0.00258	CbGeAlD
Dasatinib—FYN—bone marrow—prostate cancer	0.000165	0.00255	CbGeAlD
Dasatinib—EPHA4—testis—prostate cancer	0.000165	0.00255	CbGeAlD
Dasatinib—ZAK—lymph node—prostate cancer	0.000165	0.00254	CbGeAlD
Dasatinib—ERBB3—testis—prostate cancer	0.000164	0.00252	CbGeAlD
Dasatinib—PDGFRB—epithelium—prostate cancer	0.000163	0.00252	CbGeAlD
Dasatinib—MAP3K2—testis—prostate cancer	0.000162	0.0025	CbGeAlD
Dasatinib—MAP3K3—bone marrow—prostate cancer	0.000162	0.0025	CbGeAlD
Dasatinib—MAP4K5—bone marrow—prostate cancer	0.000162	0.0025	CbGeAlD
Dasatinib—BMPR1B—lymph node—prostate cancer	0.000158	0.00244	CbGeAlD
Dasatinib—BTK—lymph node—prostate cancer	0.000157	0.00243	CbGeAlD
Dasatinib—TNK2—lymph node—prostate cancer	0.000155	0.00239	CbGeAlD
Dasatinib—KIT—renal system—prostate cancer	0.000155	0.00239	CbGeAlD
Dasatinib—TESK1—Estradiol—Estrone—prostate cancer	0.000154	0.0766	CbGdCrCtD
Dasatinib—MAPK14—testis—prostate cancer	0.000152	0.00235	CbGeAlD
Dasatinib—KIT—urethra—prostate cancer	0.000152	0.00235	CbGeAlD
Dasatinib—LCK—testis—prostate cancer	0.000152	0.00234	CbGeAlD
Dasatinib—FGR—testis—prostate cancer	0.000152	0.00234	CbGeAlD
Dasatinib—PDGFRB—renal system—prostate cancer	0.000151	0.00233	CbGeAlD
Dasatinib—YES1—bone marrow—prostate cancer	0.000149	0.0023	CbGeAlD
Dasatinib—PDGFRB—urethra—prostate cancer	0.000149	0.00229	CbGeAlD
Dasatinib—FMO3—testis—prostate cancer	0.000147	0.00226	CbGeAlD
Dasatinib—TESK1—lymph node—prostate cancer	0.000146	0.00225	CbGeAlD
Dasatinib—EPHB4—testis—prostate cancer	0.000144	0.00223	CbGeAlD
Dasatinib—JAK2—testis—prostate cancer	0.000143	0.00221	CbGeAlD
Dasatinib—EPHB3—lymph node—prostate cancer	0.000143	0.00221	CbGeAlD
Dasatinib—STK36—lymph node—prostate cancer	0.000143	0.00221	CbGeAlD
Dasatinib—EPHA2—testis—prostate cancer	0.000142	0.00219	CbGeAlD
Dasatinib—FYN—testis—prostate cancer	0.000141	0.00218	CbGeAlD
Dasatinib—LIMK2—lymph node—prostate cancer	0.000139	0.00214	CbGeAlD
Dasatinib—MAP4K5—testis—prostate cancer	0.000138	0.00213	CbGeAlD
Dasatinib—MAP3K3—testis—prostate cancer	0.000138	0.00213	CbGeAlD
Dasatinib—TESK1—Estradiol—Conjugated Estrogens—prostate cancer	0.000136	0.0674	CbGdCrCtD
Dasatinib—ABL1—renal system—prostate cancer	0.000135	0.00208	CbGeAlD
Dasatinib—STK35—lymph node—prostate cancer	0.000134	0.00207	CbGeAlD
Dasatinib—CSK—lymph node—prostate cancer	0.000133	0.00206	CbGeAlD
Dasatinib—ABL1—urethra—prostate cancer	0.000132	0.00204	CbGeAlD
Dasatinib—EPHB6—testis—prostate cancer	0.000132	0.00204	CbGeAlD
Dasatinib—HCK—lymph node—prostate cancer	0.000132	0.00203	CbGeAlD
Dasatinib—ABL2—lymph node—prostate cancer	0.000131	0.00202	CbGeAlD
Dasatinib—ERBB3—Podofilox—Etoposide—prostate cancer	0.00013	0.0642	CbGdCrCtD
Dasatinib—CSF1R—bone marrow—prostate cancer	0.000129	0.00199	CbGeAlD
Dasatinib—YES1—testis—prostate cancer	0.000128	0.00197	CbGeAlD
Dasatinib—PDGFRA—testis—prostate cancer	0.000125	0.00193	CbGeAlD
Dasatinib—ABCG2—prostate gland—prostate cancer	0.000125	0.00193	CbGeAlD
Dasatinib—RIPK2—lymph node—prostate cancer	0.000124	0.00191	CbGeAlD
Dasatinib—SRC—testis—prostate cancer	0.000123	0.0019	CbGeAlD
Dasatinib—SIK1—lymph node—prostate cancer	0.000121	0.00187	CbGeAlD
Dasatinib—EPHA4—lymph node—prostate cancer	0.00012	0.00185	CbGeAlD
Dasatinib—ERBB3—lymph node—prostate cancer	0.000119	0.00183	CbGeAlD
Dasatinib—MAP3K2—lymph node—prostate cancer	0.000117	0.00181	CbGeAlD
Dasatinib—KIT—bone marrow—prostate cancer	0.000117	0.00181	CbGeAlD
Dasatinib—CYP3A5—prostate gland—prostate cancer	0.000116	0.00179	CbGeAlD
Dasatinib—PDGFRB—bone marrow—prostate cancer	0.000114	0.00177	CbGeAlD
Dasatinib—TESK1—Estradiol—Ethinyl Estradiol—prostate cancer	0.000114	0.0566	CbGdCrCtD
Dasatinib—CYP1B1—renal system—prostate cancer	0.000114	0.00176	CbGeAlD
Dasatinib—MAP2K5—testis—prostate cancer	0.000113	0.00174	CbGeAlD
Dasatinib—MAPK14—lymph node—prostate cancer	0.00011	0.0017	CbGeAlD
Dasatinib—CSF1R—testis—prostate cancer	0.00011	0.0017	CbGeAlD
Dasatinib—FGR—lymph node—prostate cancer	0.00011	0.0017	CbGeAlD
Dasatinib—LCK—lymph node—prostate cancer	0.00011	0.0017	CbGeAlD
Dasatinib—FMO3—lymph node—prostate cancer	0.000106	0.00164	CbGeAlD
Dasatinib—ABCG2—seminal vesicle—prostate cancer	0.000105	0.00163	CbGeAlD
Dasatinib—EPHB4—lymph node—prostate cancer	0.000105	0.00162	CbGeAlD
Dasatinib—JAK2—lymph node—prostate cancer	0.000104	0.0016	CbGeAlD
Dasatinib—EPHA2—lymph node—prostate cancer	0.000103	0.00158	CbGeAlD
Dasatinib—FYN—lymph node—prostate cancer	0.000103	0.00158	CbGeAlD
Dasatinib—ABL1—bone marrow—prostate cancer	0.000102	0.00157	CbGeAlD
Dasatinib—MAP4K5—lymph node—prostate cancer	0.0001	0.00155	CbGeAlD
Dasatinib—MAP3K3—lymph node—prostate cancer	0.0001	0.00155	CbGeAlD
Dasatinib—KIT—testis—prostate cancer	0.0001	0.00154	CbGeAlD
Dasatinib—PDGFRB—testis—prostate cancer	9.78e-05	0.00151	CbGeAlD
Dasatinib—EPHB6—lymph node—prostate cancer	9.57e-05	0.00148	CbGeAlD
Dasatinib—YES1—lymph node—prostate cancer	9.25e-05	0.00143	CbGeAlD
Dasatinib—PDGFRA—lymph node—prostate cancer	9.08e-05	0.0014	CbGeAlD
Dasatinib—SRC—lymph node—prostate cancer	8.9e-05	0.00137	CbGeAlD
Dasatinib—PKMYT1—Danazol—Ethinyl Estradiol—prostate cancer	8.88e-05	0.044	CbGdCrCtD
Dasatinib—ABL1—testis—prostate cancer	8.71e-05	0.00134	CbGeAlD
Dasatinib—CYP1A1—epithelium—prostate cancer	8.7e-05	0.00134	CbGeAlD
Dasatinib—ABCG2—urethra—prostate cancer	8.35e-05	0.00129	CbGeAlD
Dasatinib—ABL1—Levorphanol—Estrone—prostate cancer	8.27e-05	0.041	CbGdCrCtD
Dasatinib—MAP2K5—lymph node—prostate cancer	8.19e-05	0.00126	CbGeAlD
Dasatinib—CYP1A2—renal system—prostate cancer	8.18e-05	0.00126	CbGeAlD
Dasatinib—CYP1A1—renal system—prostate cancer	8.07e-05	0.00125	CbGeAlD
Dasatinib—CSF1R—lymph node—prostate cancer	7.99e-05	0.00123	CbGeAlD
Dasatinib—CYP1A1—urethra—prostate cancer	7.93e-05	0.00122	CbGeAlD
Dasatinib—CYP3A5—renal system—prostate cancer	7.89e-05	0.00122	CbGeAlD
Dasatinib—CYP1B1—testis—prostate cancer	7.38e-05	0.00114	CbGeAlD
Dasatinib—KIT—lymph node—prostate cancer	7.26e-05	0.00112	CbGeAlD
Dasatinib—PDGFRB—lymph node—prostate cancer	7.09e-05	0.00109	CbGeAlD
Dasatinib—ABCG2—bone marrow—prostate cancer	6.43e-05	0.000992	CbGeAlD
Dasatinib—ABL1—lymph node—prostate cancer	6.32e-05	0.000975	CbGeAlD
Dasatinib—ABL1—Levorphanol—Estradiol—prostate cancer	6.27e-05	0.0311	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Epirubicin—prostate cancer	6.23e-05	0.0309	CbGdCrCtD
Dasatinib—CSK—Doxorubicin—Epirubicin—prostate cancer	6.23e-05	0.0309	CbGdCrCtD
Dasatinib—ABCB1—prostate gland—prostate cancer	6.15e-05	0.000949	CbGeAlD
Dasatinib—CYP3A4—renal system—prostate cancer	5.92e-05	0.000914	CbGeAlD
Dasatinib—CSK—Epirubicin—Doxorubicin—prostate cancer	5.77e-05	0.0286	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Doxorubicin—prostate cancer	5.77e-05	0.0286	CbGdCrCtD
Dasatinib—EPHB2—Diflorasone—Prednisone—prostate cancer	5.5e-05	0.0273	CbGdCrCtD
Dasatinib—ABCG2—testis—prostate cancer	5.49e-05	0.000848	CbGeAlD
Dasatinib—CYP1B1—lymph node—prostate cancer	5.35e-05	0.000826	CbGeAlD
Dasatinib—ABCB1—seminal vesicle—prostate cancer	5.2e-05	0.000803	CbGeAlD
Dasatinib—ABCB1—epithelium—prostate cancer	4.52e-05	0.000698	CbGeAlD
Dasatinib—ABL1—Doxorubicin—Epirubicin—prostate cancer	4.35e-05	0.0216	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Epirubicin—prostate cancer	4.35e-05	0.0216	CbGdCrCtD
Dasatinib—ABL1—Idarubicin—Epirubicin—prostate cancer	4.35e-05	0.0216	CbGdCrCtD
Dasatinib—ABCB1—renal system—prostate cancer	4.19e-05	0.000647	CbGeAlD
Dasatinib—ABCB1—urethra—prostate cancer	4.12e-05	0.000636	CbGeAlD
Dasatinib—ABL1—Daunorubicin—Doxorubicin—prostate cancer	4.03e-05	0.02	CbGdCrCtD
Dasatinib—ABL1—Epirubicin—Doxorubicin—prostate cancer	4.03e-05	0.02	CbGdCrCtD
Dasatinib—ABL1—Idarubicin—Doxorubicin—prostate cancer	4.03e-05	0.02	CbGdCrCtD
Dasatinib—ABCG2—lymph node—prostate cancer	3.98e-05	0.000615	CbGeAlD
Dasatinib—CYP1A1—lymph node—prostate cancer	3.78e-05	0.000584	CbGeAlD
Dasatinib—ABCB1—bone marrow—prostate cancer	3.17e-05	0.000489	CbGeAlD
Dasatinib—PKMYT1—Danazol—Prednisone—prostate cancer	3.12e-05	0.0155	CbGdCrCtD
Dasatinib—ABCB1—testis—prostate cancer	2.71e-05	0.000418	CbGeAlD
Dasatinib—TESK1—Betamethasone—Prednisone—prostate cancer	2.23e-05	0.0111	CbGdCrCtD
Dasatinib—TESK1—Dexamethasone—Prednisone—prostate cancer	2.23e-05	0.0111	CbGdCrCtD
Dasatinib—ABCB1—lymph node—prostate cancer	1.96e-05	0.000303	CbGeAlD
Dasatinib—Epistaxis—Doxorubicin—prostate cancer	1.7e-05	0.000152	CcSEcCtD
Dasatinib—Anorexia—Capecitabine—prostate cancer	1.7e-05	0.000152	CcSEcCtD
Dasatinib—Nausea—Estradiol—prostate cancer	1.69e-05	0.000152	CcSEcCtD
Dasatinib—Vomiting—Mitoxantrone—prostate cancer	1.69e-05	0.000152	CcSEcCtD
Dasatinib—Convulsion—Prednisone—prostate cancer	1.68e-05	0.000151	CcSEcCtD
Dasatinib—Visual impairment—Epirubicin—prostate cancer	1.68e-05	0.000151	CcSEcCtD
Dasatinib—Hypertension—Prednisone—prostate cancer	1.68e-05	0.000151	CcSEcCtD
Dasatinib—Rash—Mitoxantrone—prostate cancer	1.68e-05	0.000151	CcSEcCtD
Dasatinib—Dermatitis—Mitoxantrone—prostate cancer	1.67e-05	0.000151	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Docetaxel—prostate cancer	1.67e-05	0.000151	CcSEcCtD
Dasatinib—Headache—Mitoxantrone—prostate cancer	1.66e-05	0.00015	CcSEcCtD
Dasatinib—Hypotension—Capecitabine—prostate cancer	1.66e-05	0.000149	CcSEcCtD
Dasatinib—Insomnia—Docetaxel—prostate cancer	1.66e-05	0.000149	CcSEcCtD
Dasatinib—Myalgia—Prednisone—prostate cancer	1.65e-05	0.000149	CcSEcCtD
Dasatinib—Arthralgia—Prednisone—prostate cancer	1.65e-05	0.000149	CcSEcCtD
Dasatinib—Erythema multiforme—Epirubicin—prostate cancer	1.65e-05	0.000148	CcSEcCtD
Dasatinib—Anxiety—Prednisone—prostate cancer	1.65e-05	0.000148	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	1.64e-05	0.000148	CcSEcCtD
Dasatinib—Dyspnoea—Docetaxel—prostate cancer	1.64e-05	0.000147	CcSEcCtD
Dasatinib—Somnolence—Docetaxel—prostate cancer	1.63e-05	0.000147	CcSEcCtD
Dasatinib—Discomfort—Prednisone—prostate cancer	1.63e-05	0.000147	CcSEcCtD
Dasatinib—Eye disorder—Epirubicin—prostate cancer	1.63e-05	0.000147	CcSEcCtD
Dasatinib—Hypersensitivity—Etoposide—prostate cancer	1.63e-05	0.000146	CcSEcCtD
Dasatinib—Tinnitus—Epirubicin—prostate cancer	1.63e-05	0.000146	CcSEcCtD
Dasatinib—Haemoglobin—Doxorubicin—prostate cancer	1.62e-05	0.000146	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Capecitabine—prostate cancer	1.62e-05	0.000146	CcSEcCtD
Dasatinib—Flushing—Epirubicin—prostate cancer	1.62e-05	0.000146	CcSEcCtD
Dasatinib—Cardiac disorder—Epirubicin—prostate cancer	1.62e-05	0.000146	CcSEcCtD
Dasatinib—Dyspepsia—Docetaxel—prostate cancer	1.62e-05	0.000145	CcSEcCtD
Dasatinib—Haemorrhage—Doxorubicin—prostate cancer	1.61e-05	0.000145	CcSEcCtD
Dasatinib—Hepatitis—Doxorubicin—prostate cancer	1.61e-05	0.000145	CcSEcCtD
Dasatinib—Insomnia—Capecitabine—prostate cancer	1.61e-05	0.000145	CcSEcCtD
Dasatinib—Decreased appetite—Docetaxel—prostate cancer	1.6e-05	0.000144	CcSEcCtD
Dasatinib—Urinary tract disorder—Doxorubicin—prostate cancer	1.59e-05	0.000143	CcSEcCtD
Dasatinib—Oedema peripheral—Doxorubicin—prostate cancer	1.59e-05	0.000143	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Docetaxel—prostate cancer	1.59e-05	0.000143	CcSEcCtD
Dasatinib—Asthenia—Etoposide—prostate cancer	1.59e-05	0.000143	CcSEcCtD
Dasatinib—Connective tissue disorder—Doxorubicin—prostate cancer	1.59e-05	0.000143	CcSEcCtD
Dasatinib—Dyspnoea—Capecitabine—prostate cancer	1.59e-05	0.000143	CcSEcCtD
Dasatinib—Oedema—Prednisone—prostate cancer	1.58e-05	0.000142	CcSEcCtD
Dasatinib—Fatigue—Docetaxel—prostate cancer	1.58e-05	0.000142	CcSEcCtD
Dasatinib—Angiopathy—Epirubicin—prostate cancer	1.58e-05	0.000142	CcSEcCtD
Dasatinib—Urethral disorder—Doxorubicin—prostate cancer	1.58e-05	0.000142	CcSEcCtD
Dasatinib—Nausea—Mitoxantrone—prostate cancer	1.58e-05	0.000142	CcSEcCtD
Dasatinib—Immune system disorder—Epirubicin—prostate cancer	1.58e-05	0.000142	CcSEcCtD
Dasatinib—Infection—Prednisone—prostate cancer	1.57e-05	0.000142	CcSEcCtD
Dasatinib—Mediastinal disorder—Epirubicin—prostate cancer	1.57e-05	0.000141	CcSEcCtD
Dasatinib—Pain—Docetaxel—prostate cancer	1.57e-05	0.000141	CcSEcCtD
Dasatinib—Constipation—Docetaxel—prostate cancer	1.57e-05	0.000141	CcSEcCtD
Dasatinib—Dyspepsia—Capecitabine—prostate cancer	1.57e-05	0.000141	CcSEcCtD
Dasatinib—Chills—Epirubicin—prostate cancer	1.56e-05	0.000141	CcSEcCtD
Dasatinib—Pruritus—Etoposide—prostate cancer	1.56e-05	0.000141	CcSEcCtD
Dasatinib—Shock—Prednisone—prostate cancer	1.56e-05	0.00014	CcSEcCtD
Dasatinib—Arrhythmia—Epirubicin—prostate cancer	1.56e-05	0.00014	CcSEcCtD
Dasatinib—Visual impairment—Doxorubicin—prostate cancer	1.56e-05	0.00014	CcSEcCtD
Dasatinib—Nervous system disorder—Prednisone—prostate cancer	1.55e-05	0.00014	CcSEcCtD
Dasatinib—Tachycardia—Prednisone—prostate cancer	1.55e-05	0.000139	CcSEcCtD
Dasatinib—Decreased appetite—Capecitabine—prostate cancer	1.55e-05	0.000139	CcSEcCtD
Dasatinib—Alopecia—Epirubicin—prostate cancer	1.54e-05	0.000139	CcSEcCtD
Dasatinib—Skin disorder—Prednisone—prostate cancer	1.54e-05	0.000138	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Capecitabine—prostate cancer	1.54e-05	0.000138	CcSEcCtD
Dasatinib—Fatigue—Capecitabine—prostate cancer	1.53e-05	0.000138	CcSEcCtD
Dasatinib—Hyperhidrosis—Prednisone—prostate cancer	1.53e-05	0.000138	CcSEcCtD
Dasatinib—Mental disorder—Epirubicin—prostate cancer	1.53e-05	0.000137	CcSEcCtD
Dasatinib—Erythema multiforme—Doxorubicin—prostate cancer	1.53e-05	0.000137	CcSEcCtD
Dasatinib—Constipation—Capecitabine—prostate cancer	1.52e-05	0.000137	CcSEcCtD
Dasatinib—Pain—Capecitabine—prostate cancer	1.52e-05	0.000137	CcSEcCtD
Dasatinib—Malnutrition—Epirubicin—prostate cancer	1.52e-05	0.000137	CcSEcCtD
Dasatinib—Erythema—Epirubicin—prostate cancer	1.52e-05	0.000137	CcSEcCtD
Dasatinib—Feeling abnormal—Docetaxel—prostate cancer	1.51e-05	0.000136	CcSEcCtD
Dasatinib—Diarrhoea—Etoposide—prostate cancer	1.51e-05	0.000136	CcSEcCtD
Dasatinib—Anorexia—Prednisone—prostate cancer	1.51e-05	0.000136	CcSEcCtD
Dasatinib—Eye disorder—Doxorubicin—prostate cancer	1.51e-05	0.000136	CcSEcCtD
Dasatinib—Tinnitus—Doxorubicin—prostate cancer	1.5e-05	0.000135	CcSEcCtD
Dasatinib—Gastrointestinal pain—Docetaxel—prostate cancer	1.5e-05	0.000135	CcSEcCtD
Dasatinib—Cardiac disorder—Doxorubicin—prostate cancer	1.5e-05	0.000135	CcSEcCtD
Dasatinib—Flushing—Doxorubicin—prostate cancer	1.5e-05	0.000135	CcSEcCtD
Dasatinib—Dysgeusia—Epirubicin—prostate cancer	1.49e-05	0.000134	CcSEcCtD
Dasatinib—Feeling abnormal—Capecitabine—prostate cancer	1.47e-05	0.000132	CcSEcCtD
Dasatinib—Angiopathy—Doxorubicin—prostate cancer	1.46e-05	0.000132	CcSEcCtD
Dasatinib—Dizziness—Etoposide—prostate cancer	1.46e-05	0.000131	CcSEcCtD
Dasatinib—Muscle spasms—Epirubicin—prostate cancer	1.46e-05	0.000131	CcSEcCtD
Dasatinib—Immune system disorder—Doxorubicin—prostate cancer	1.46e-05	0.000131	CcSEcCtD
Dasatinib—Gastrointestinal pain—Capecitabine—prostate cancer	1.45e-05	0.000131	CcSEcCtD
Dasatinib—Mediastinal disorder—Doxorubicin—prostate cancer	1.45e-05	0.000131	CcSEcCtD
Dasatinib—Abdominal pain—Docetaxel—prostate cancer	1.45e-05	0.000131	CcSEcCtD
Dasatinib—Body temperature increased—Docetaxel—prostate cancer	1.45e-05	0.000131	CcSEcCtD
Dasatinib—Chills—Doxorubicin—prostate cancer	1.45e-05	0.00013	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Prednisone—prostate cancer	1.44e-05	0.00013	CcSEcCtD
Dasatinib—Arrhythmia—Doxorubicin—prostate cancer	1.44e-05	0.00013	CcSEcCtD
Dasatinib—Insomnia—Prednisone—prostate cancer	1.43e-05	0.000129	CcSEcCtD
Dasatinib—Vision blurred—Epirubicin—prostate cancer	1.43e-05	0.000129	CcSEcCtD
Dasatinib—Alopecia—Doxorubicin—prostate cancer	1.43e-05	0.000128	CcSEcCtD
Dasatinib—Mental disorder—Doxorubicin—prostate cancer	1.41e-05	0.000127	CcSEcCtD
Dasatinib—Urticaria—Capecitabine—prostate cancer	1.41e-05	0.000127	CcSEcCtD
Dasatinib—Ill-defined disorder—Epirubicin—prostate cancer	1.41e-05	0.000127	CcSEcCtD
Dasatinib—Abdominal pain—Capecitabine—prostate cancer	1.41e-05	0.000126	CcSEcCtD
Dasatinib—Body temperature increased—Capecitabine—prostate cancer	1.41e-05	0.000126	CcSEcCtD
Dasatinib—Vomiting—Etoposide—prostate cancer	1.41e-05	0.000126	CcSEcCtD
Dasatinib—Erythema—Doxorubicin—prostate cancer	1.4e-05	0.000126	CcSEcCtD
Dasatinib—Malnutrition—Doxorubicin—prostate cancer	1.4e-05	0.000126	CcSEcCtD
Dasatinib—Anaemia—Epirubicin—prostate cancer	1.4e-05	0.000126	CcSEcCtD
Dasatinib—Dyspepsia—Prednisone—prostate cancer	1.39e-05	0.000125	CcSEcCtD
Dasatinib—Rash—Etoposide—prostate cancer	1.39e-05	0.000125	CcSEcCtD
Dasatinib—Dermatitis—Etoposide—prostate cancer	1.39e-05	0.000125	CcSEcCtD
Dasatinib—Headache—Etoposide—prostate cancer	1.38e-05	0.000125	CcSEcCtD
Dasatinib—Decreased appetite—Prednisone—prostate cancer	1.38e-05	0.000124	CcSEcCtD
Dasatinib—Dysgeusia—Doxorubicin—prostate cancer	1.38e-05	0.000124	CcSEcCtD
Dasatinib—Malaise—Epirubicin—prostate cancer	1.37e-05	0.000123	CcSEcCtD
Dasatinib—Fatigue—Prednisone—prostate cancer	1.37e-05	0.000123	CcSEcCtD
Dasatinib—Vertigo—Epirubicin—prostate cancer	1.36e-05	0.000123	CcSEcCtD
Dasatinib—Syncope—Epirubicin—prostate cancer	1.36e-05	0.000122	CcSEcCtD
Dasatinib—Constipation—Prednisone—prostate cancer	1.35e-05	0.000122	CcSEcCtD
Dasatinib—Hypersensitivity—Docetaxel—prostate cancer	1.35e-05	0.000122	CcSEcCtD
Dasatinib—Muscle spasms—Doxorubicin—prostate cancer	1.35e-05	0.000121	CcSEcCtD
Dasatinib—Palpitations—Epirubicin—prostate cancer	1.34e-05	0.000121	CcSEcCtD
Dasatinib—Loss of consciousness—Epirubicin—prostate cancer	1.33e-05	0.00012	CcSEcCtD
Dasatinib—Cough—Epirubicin—prostate cancer	1.32e-05	0.000119	CcSEcCtD
Dasatinib—Vision blurred—Doxorubicin—prostate cancer	1.32e-05	0.000119	CcSEcCtD
Dasatinib—Asthenia—Docetaxel—prostate cancer	1.32e-05	0.000119	CcSEcCtD
Dasatinib—Convulsion—Epirubicin—prostate cancer	1.32e-05	0.000118	CcSEcCtD
Dasatinib—Nausea—Etoposide—prostate cancer	1.31e-05	0.000118	CcSEcCtD
Dasatinib—Hypertension—Epirubicin—prostate cancer	1.31e-05	0.000118	CcSEcCtD
Dasatinib—Hypersensitivity—Capecitabine—prostate cancer	1.31e-05	0.000118	CcSEcCtD
Dasatinib—Feeling abnormal—Prednisone—prostate cancer	1.31e-05	0.000117	CcSEcCtD
Dasatinib—Ill-defined disorder—Doxorubicin—prostate cancer	1.3e-05	0.000117	CcSEcCtD
Dasatinib—Pruritus—Docetaxel—prostate cancer	1.3e-05	0.000117	CcSEcCtD
Dasatinib—Anaemia—Doxorubicin—prostate cancer	1.3e-05	0.000117	CcSEcCtD
Dasatinib—Gastrointestinal pain—Prednisone—prostate cancer	1.3e-05	0.000117	CcSEcCtD
Dasatinib—Myalgia—Epirubicin—prostate cancer	1.29e-05	0.000116	CcSEcCtD
Dasatinib—Chest pain—Epirubicin—prostate cancer	1.29e-05	0.000116	CcSEcCtD
Dasatinib—Arthralgia—Epirubicin—prostate cancer	1.29e-05	0.000116	CcSEcCtD
Dasatinib—Anxiety—Epirubicin—prostate cancer	1.29e-05	0.000116	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	1.28e-05	0.000115	CcSEcCtD
Dasatinib—Discomfort—Epirubicin—prostate cancer	1.28e-05	0.000115	CcSEcCtD
Dasatinib—Asthenia—Capecitabine—prostate cancer	1.28e-05	0.000115	CcSEcCtD
Dasatinib—Malaise—Doxorubicin—prostate cancer	1.27e-05	0.000114	CcSEcCtD
Dasatinib—Vertigo—Doxorubicin—prostate cancer	1.26e-05	0.000114	CcSEcCtD
Dasatinib—Syncope—Doxorubicin—prostate cancer	1.26e-05	0.000113	CcSEcCtD
Dasatinib—Urticaria—Prednisone—prostate cancer	1.26e-05	0.000113	CcSEcCtD
Dasatinib—Pruritus—Capecitabine—prostate cancer	1.26e-05	0.000113	CcSEcCtD
Dasatinib—Diarrhoea—Docetaxel—prostate cancer	1.26e-05	0.000113	CcSEcCtD
Dasatinib—Body temperature increased—Prednisone—prostate cancer	1.25e-05	0.000113	CcSEcCtD
Dasatinib—Abdominal pain—Prednisone—prostate cancer	1.25e-05	0.000113	CcSEcCtD
Dasatinib—Confusional state—Epirubicin—prostate cancer	1.25e-05	0.000112	CcSEcCtD
Dasatinib—Palpitations—Doxorubicin—prostate cancer	1.24e-05	0.000112	CcSEcCtD
Dasatinib—Oedema—Epirubicin—prostate cancer	1.24e-05	0.000111	CcSEcCtD
Dasatinib—Loss of consciousness—Doxorubicin—prostate cancer	1.23e-05	0.000111	CcSEcCtD
Dasatinib—Infection—Epirubicin—prostate cancer	1.23e-05	0.000111	CcSEcCtD
Dasatinib—Cough—Doxorubicin—prostate cancer	1.23e-05	0.00011	CcSEcCtD
Dasatinib—Shock—Epirubicin—prostate cancer	1.22e-05	0.00011	CcSEcCtD
Dasatinib—Convulsion—Doxorubicin—prostate cancer	1.22e-05	0.000109	CcSEcCtD
Dasatinib—Diarrhoea—Capecitabine—prostate cancer	1.22e-05	0.000109	CcSEcCtD
Dasatinib—Nervous system disorder—Epirubicin—prostate cancer	1.22e-05	0.000109	CcSEcCtD
Dasatinib—Dizziness—Docetaxel—prostate cancer	1.21e-05	0.000109	CcSEcCtD
Dasatinib—Thrombocytopenia—Epirubicin—prostate cancer	1.21e-05	0.000109	CcSEcCtD
Dasatinib—Hypertension—Doxorubicin—prostate cancer	1.21e-05	0.000109	CcSEcCtD
Dasatinib—Tachycardia—Epirubicin—prostate cancer	1.21e-05	0.000109	CcSEcCtD
Dasatinib—Skin disorder—Epirubicin—prostate cancer	1.2e-05	0.000108	CcSEcCtD
Dasatinib—Hyperhidrosis—Epirubicin—prostate cancer	1.2e-05	0.000108	CcSEcCtD
Dasatinib—Arthralgia—Doxorubicin—prostate cancer	1.2e-05	0.000108	CcSEcCtD
Dasatinib—Chest pain—Doxorubicin—prostate cancer	1.2e-05	0.000108	CcSEcCtD
Dasatinib—Myalgia—Doxorubicin—prostate cancer	1.2e-05	0.000108	CcSEcCtD
Dasatinib—Anxiety—Doxorubicin—prostate cancer	1.19e-05	0.000107	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	1.19e-05	0.000107	CcSEcCtD
Dasatinib—Discomfort—Doxorubicin—prostate cancer	1.18e-05	0.000106	CcSEcCtD
Dasatinib—Anorexia—Epirubicin—prostate cancer	1.18e-05	0.000106	CcSEcCtD
Dasatinib—Dizziness—Capecitabine—prostate cancer	1.18e-05	0.000106	CcSEcCtD
Dasatinib—Vomiting—Docetaxel—prostate cancer	1.17e-05	0.000105	CcSEcCtD
Dasatinib—Hypersensitivity—Prednisone—prostate cancer	1.17e-05	0.000105	CcSEcCtD
Dasatinib—Rash—Docetaxel—prostate cancer	1.16e-05	0.000104	CcSEcCtD
Dasatinib—Hypotension—Epirubicin—prostate cancer	1.16e-05	0.000104	CcSEcCtD
Dasatinib—Dermatitis—Docetaxel—prostate cancer	1.16e-05	0.000104	CcSEcCtD
Dasatinib—Confusional state—Doxorubicin—prostate cancer	1.16e-05	0.000104	CcSEcCtD
Dasatinib—Headache—Docetaxel—prostate cancer	1.15e-05	0.000104	CcSEcCtD
Dasatinib—Oedema—Doxorubicin—prostate cancer	1.15e-05	0.000103	CcSEcCtD
Dasatinib—Infection—Doxorubicin—prostate cancer	1.14e-05	0.000102	CcSEcCtD
Dasatinib—Asthenia—Prednisone—prostate cancer	1.14e-05	0.000102	CcSEcCtD
Dasatinib—Vomiting—Capecitabine—prostate cancer	1.13e-05	0.000102	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Epirubicin—prostate cancer	1.13e-05	0.000102	CcSEcCtD
Dasatinib—Shock—Doxorubicin—prostate cancer	1.13e-05	0.000101	CcSEcCtD
Dasatinib—Nervous system disorder—Doxorubicin—prostate cancer	1.12e-05	0.000101	CcSEcCtD
Dasatinib—Thrombocytopenia—Doxorubicin—prostate cancer	1.12e-05	0.000101	CcSEcCtD
Dasatinib—Rash—Capecitabine—prostate cancer	1.12e-05	0.000101	CcSEcCtD
Dasatinib—Pruritus—Prednisone—prostate cancer	1.12e-05	0.000101	CcSEcCtD
Dasatinib—Insomnia—Epirubicin—prostate cancer	1.12e-05	0.000101	CcSEcCtD
Dasatinib—Dermatitis—Capecitabine—prostate cancer	1.12e-05	0.000101	CcSEcCtD
Dasatinib—Tachycardia—Doxorubicin—prostate cancer	1.12e-05	0.000101	CcSEcCtD
Dasatinib—Headache—Capecitabine—prostate cancer	1.11e-05	0.0001	CcSEcCtD
Dasatinib—Skin disorder—Doxorubicin—prostate cancer	1.11e-05	0.0001	CcSEcCtD
Dasatinib—Hyperhidrosis—Doxorubicin—prostate cancer	1.11e-05	9.97e-05	CcSEcCtD
Dasatinib—Dyspnoea—Epirubicin—prostate cancer	1.1e-05	9.94e-05	CcSEcCtD
Dasatinib—Somnolence—Epirubicin—prostate cancer	1.1e-05	9.91e-05	CcSEcCtD
Dasatinib—Anorexia—Doxorubicin—prostate cancer	1.09e-05	9.83e-05	CcSEcCtD
Dasatinib—Nausea—Docetaxel—prostate cancer	1.09e-05	9.81e-05	CcSEcCtD
Dasatinib—Dyspepsia—Epirubicin—prostate cancer	1.09e-05	9.81e-05	CcSEcCtD
Dasatinib—Diarrhoea—Prednisone—prostate cancer	1.08e-05	9.75e-05	CcSEcCtD
Dasatinib—Decreased appetite—Epirubicin—prostate cancer	1.08e-05	9.69e-05	CcSEcCtD
Dasatinib—Hypotension—Doxorubicin—prostate cancer	1.07e-05	9.63e-05	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Epirubicin—prostate cancer	1.07e-05	9.62e-05	CcSEcCtD
Dasatinib—Fatigue—Epirubicin—prostate cancer	1.07e-05	9.61e-05	CcSEcCtD
Dasatinib—Pain—Epirubicin—prostate cancer	1.06e-05	9.53e-05	CcSEcCtD
Dasatinib—Constipation—Epirubicin—prostate cancer	1.06e-05	9.53e-05	CcSEcCtD
Dasatinib—Nausea—Capecitabine—prostate cancer	1.06e-05	9.5e-05	CcSEcCtD
Dasatinib—Dizziness—Prednisone—prostate cancer	1.05e-05	9.42e-05	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.04e-05	9.39e-05	CcSEcCtD
Dasatinib—Insomnia—Doxorubicin—prostate cancer	1.04e-05	9.33e-05	CcSEcCtD
Dasatinib—Dyspnoea—Doxorubicin—prostate cancer	1.02e-05	9.19e-05	CcSEcCtD
Dasatinib—Feeling abnormal—Epirubicin—prostate cancer	1.02e-05	9.18e-05	CcSEcCtD
Dasatinib—Somnolence—Doxorubicin—prostate cancer	1.02e-05	9.17e-05	CcSEcCtD
Dasatinib—Gastrointestinal pain—Epirubicin—prostate cancer	1.01e-05	9.11e-05	CcSEcCtD
Dasatinib—Dyspepsia—Doxorubicin—prostate cancer	1.01e-05	9.08e-05	CcSEcCtD
Dasatinib—Vomiting—Prednisone—prostate cancer	1.01e-05	9.06e-05	CcSEcCtD
Dasatinib—Rash—Prednisone—prostate cancer	9.99e-06	8.98e-05	CcSEcCtD
Dasatinib—Dermatitis—Prednisone—prostate cancer	9.98e-06	8.98e-05	CcSEcCtD
Dasatinib—Decreased appetite—Doxorubicin—prostate cancer	9.97e-06	8.96e-05	CcSEcCtD
Dasatinib—Headache—Prednisone—prostate cancer	9.92e-06	8.93e-05	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Doxorubicin—prostate cancer	9.9e-06	8.9e-05	CcSEcCtD
Dasatinib—Fatigue—Doxorubicin—prostate cancer	9.88e-06	8.89e-05	CcSEcCtD
Dasatinib—Urticaria—Epirubicin—prostate cancer	9.84e-06	8.85e-05	CcSEcCtD
Dasatinib—Pain—Doxorubicin—prostate cancer	9.8e-06	8.82e-05	CcSEcCtD
Dasatinib—Constipation—Doxorubicin—prostate cancer	9.8e-06	8.82e-05	CcSEcCtD
Dasatinib—Body temperature increased—Epirubicin—prostate cancer	9.79e-06	8.81e-05	CcSEcCtD
Dasatinib—Abdominal pain—Epirubicin—prostate cancer	9.79e-06	8.81e-05	CcSEcCtD
Dasatinib—Feeling abnormal—Doxorubicin—prostate cancer	9.45e-06	8.5e-05	CcSEcCtD
Dasatinib—Nausea—Prednisone—prostate cancer	9.41e-06	8.46e-05	CcSEcCtD
Dasatinib—Gastrointestinal pain—Doxorubicin—prostate cancer	9.37e-06	8.43e-05	CcSEcCtD
Dasatinib—Hypersensitivity—Epirubicin—prostate cancer	9.13e-06	8.21e-05	CcSEcCtD
Dasatinib—Urticaria—Doxorubicin—prostate cancer	9.11e-06	8.19e-05	CcSEcCtD
Dasatinib—Body temperature increased—Doxorubicin—prostate cancer	9.06e-06	8.15e-05	CcSEcCtD
Dasatinib—Abdominal pain—Doxorubicin—prostate cancer	9.06e-06	8.15e-05	CcSEcCtD
Dasatinib—Asthenia—Epirubicin—prostate cancer	8.89e-06	8e-05	CcSEcCtD
Dasatinib—Pruritus—Epirubicin—prostate cancer	8.77e-06	7.88e-05	CcSEcCtD
Dasatinib—Diarrhoea—Epirubicin—prostate cancer	8.48e-06	7.62e-05	CcSEcCtD
Dasatinib—Hypersensitivity—Doxorubicin—prostate cancer	8.45e-06	7.6e-05	CcSEcCtD
Dasatinib—Asthenia—Doxorubicin—prostate cancer	8.23e-06	7.4e-05	CcSEcCtD
Dasatinib—Dizziness—Epirubicin—prostate cancer	8.19e-06	7.37e-05	CcSEcCtD
Dasatinib—Pruritus—Doxorubicin—prostate cancer	8.11e-06	7.3e-05	CcSEcCtD
Dasatinib—Vomiting—Epirubicin—prostate cancer	7.88e-06	7.09e-05	CcSEcCtD
Dasatinib—Diarrhoea—Doxorubicin—prostate cancer	7.84e-06	7.05e-05	CcSEcCtD
Dasatinib—Rash—Epirubicin—prostate cancer	7.81e-06	7.03e-05	CcSEcCtD
Dasatinib—Dermatitis—Epirubicin—prostate cancer	7.8e-06	7.02e-05	CcSEcCtD
Dasatinib—Headache—Epirubicin—prostate cancer	7.76e-06	6.98e-05	CcSEcCtD
Dasatinib—Dizziness—Doxorubicin—prostate cancer	7.58e-06	6.82e-05	CcSEcCtD
Dasatinib—Nausea—Epirubicin—prostate cancer	7.36e-06	6.62e-05	CcSEcCtD
Dasatinib—Vomiting—Doxorubicin—prostate cancer	7.29e-06	6.56e-05	CcSEcCtD
Dasatinib—Rash—Doxorubicin—prostate cancer	7.23e-06	6.5e-05	CcSEcCtD
Dasatinib—Dermatitis—Doxorubicin—prostate cancer	7.22e-06	6.5e-05	CcSEcCtD
Dasatinib—Headache—Doxorubicin—prostate cancer	7.18e-06	6.46e-05	CcSEcCtD
Dasatinib—Nausea—Doxorubicin—prostate cancer	6.81e-06	6.12e-05	CcSEcCtD
Dasatinib—PDGFRA—Disease—AKT1—prostate cancer	2.11e-07	1.69e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—SRC—prostate cancer	2.1e-07	1.68e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—STAT3—prostate cancer	2.09e-07	1.68e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—MTHFR—prostate cancer	2.08e-07	1.68e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—VEGFA—prostate cancer	2.08e-07	1.67e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—FGF2—prostate cancer	2.08e-07	1.67e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EGFR—prostate cancer	2.08e-07	1.67e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.08e-07	1.67e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—KRAS—prostate cancer	2.08e-07	1.67e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—INS—prostate cancer	2.08e-07	1.67e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL6—prostate cancer	2.07e-07	1.66e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—prostate cancer	2.07e-07	1.66e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—STAT3—prostate cancer	2.06e-07	1.66e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—AKT1—prostate cancer	2.06e-07	1.66e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—SRC—prostate cancer	2.06e-07	1.66e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—AKT1—prostate cancer	2.06e-07	1.66e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—EGFR—prostate cancer	2.06e-07	1.66e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CXCL8—prostate cancer	2.06e-07	1.65e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—COMT—prostate cancer	2.06e-07	1.65e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—IL6—prostate cancer	2.06e-07	1.65e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NCOA2—prostate cancer	2.06e-07	1.65e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—AKT1—prostate cancer	2.06e-07	1.65e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NOS3—prostate cancer	2.06e-07	1.65e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTP1—prostate cancer	2.05e-07	1.65e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—EP300—prostate cancer	2.05e-07	1.64e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PPARA—prostate cancer	2.05e-07	1.64e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL6—prostate cancer	2.04e-07	1.64e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EP300—prostate cancer	2.04e-07	1.64e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CD—prostate cancer	2.04e-07	1.64e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—prostate cancer	2.04e-07	1.64e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CREBBP—prostate cancer	2.03e-07	1.63e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—KRAS—prostate cancer	2.03e-07	1.63e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—PIK3CA—prostate cancer	2.02e-07	1.62e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—STAT3—prostate cancer	2.02e-07	1.62e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ITPR1—prostate cancer	2.02e-07	1.62e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EP300—prostate cancer	2.02e-07	1.62e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—AKT1—prostate cancer	2.01e-07	1.62e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CDKN1B—prostate cancer	2.01e-07	1.62e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—prostate cancer	2.01e-07	1.61e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—AKT1—prostate cancer	2e-07	1.61e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—JAK2—prostate cancer	2e-07	1.61e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—STAT3—prostate cancer	1.99e-07	1.6e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—AKT1—prostate cancer	1.99e-07	1.6e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—SRC—prostate cancer	1.99e-07	1.6e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—IL6—prostate cancer	1.98e-07	1.59e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.98e-07	1.59e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—AKT1—prostate cancer	1.98e-07	1.59e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CASP3—prostate cancer	1.97e-07	1.58e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL2—prostate cancer	1.97e-07	1.58e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KRAS—prostate cancer	1.97e-07	1.58e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.96e-07	1.58e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—SRC—prostate cancer	1.96e-07	1.58e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MDM2—prostate cancer	1.95e-07	1.57e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—KRAS—prostate cancer	1.95e-07	1.56e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MYC—prostate cancer	1.95e-07	1.56e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—TGFB1—prostate cancer	1.94e-07	1.56e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—prostate cancer	1.93e-07	1.55e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CD—prostate cancer	1.93e-07	1.55e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—NOS3—prostate cancer	1.93e-07	1.55e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CAV1—prostate cancer	1.92e-07	1.55e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ERBB2—prostate cancer	1.92e-07	1.54e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCND1—prostate cancer	1.92e-07	1.54e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.92e-07	1.54e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MYC—prostate cancer	1.92e-07	1.54e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—STAT3—prostate cancer	1.92e-07	1.54e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TGFB1—prostate cancer	1.91e-07	1.54e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—prostate cancer	1.91e-07	1.53e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—AKT1—prostate cancer	1.91e-07	1.53e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—PIK3CA—prostate cancer	1.91e-07	1.53e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—TYMS—prostate cancer	1.91e-07	1.53e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—EGFR—prostate cancer	1.9e-07	1.53e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CTNNB1—prostate cancer	1.9e-07	1.53e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—AKT1—prostate cancer	1.9e-07	1.53e-06	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—AKT1—prostate cancer	1.9e-07	1.53e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CB—prostate cancer	1.9e-07	1.52e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NQO1—prostate cancer	1.9e-07	1.52e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL6—prostate cancer	1.89e-07	1.52e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—STAT3—prostate cancer	1.89e-07	1.52e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—IL6—prostate cancer	1.89e-07	1.52e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—AKT1—prostate cancer	1.88e-07	1.51e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTM1—prostate cancer	1.88e-07	1.51e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MYC—prostate cancer	1.88e-07	1.51e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EGFR—prostate cancer	1.88e-07	1.51e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TGFB1—prostate cancer	1.87e-07	1.5e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TH—prostate cancer	1.87e-07	1.5e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—PIK3CA—prostate cancer	1.87e-07	1.5e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MMP9—prostate cancer	1.86e-07	1.5e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CDKN1A—prostate cancer	1.86e-07	1.49e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PTEN—prostate cancer	1.85e-07	1.49e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—LPL—prostate cancer	1.85e-07	1.49e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MYC—prostate cancer	1.85e-07	1.49e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—prostate cancer	1.85e-07	1.48e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TGFB1—prostate cancer	1.84e-07	1.48e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EGFR—prostate cancer	1.84e-07	1.48e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—AKT1—prostate cancer	1.83e-07	1.47e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CXCL8—prostate cancer	1.82e-07	1.46e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—NOS3—prostate cancer	1.82e-07	1.46e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.82e-07	1.46e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EGFR—prostate cancer	1.81e-07	1.45e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PIK3CA—prostate cancer	1.81e-07	1.45e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—KRAS—prostate cancer	1.8e-07	1.44e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL6—prostate cancer	1.79e-07	1.44e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—PIK3CA—prostate cancer	1.79e-07	1.44e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYP1A1—prostate cancer	1.79e-07	1.43e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CDKN1B—prostate cancer	1.78e-07	1.43e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MYC—prostate cancer	1.78e-07	1.43e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CB—prostate cancer	1.78e-07	1.43e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TGFB1—prostate cancer	1.78e-07	1.43e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KRAS—prostate cancer	1.77e-07	1.42e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ERCC2—prostate cancer	1.77e-07	1.42e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EP300—prostate cancer	1.77e-07	1.42e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTGS2—prostate cancer	1.76e-07	1.42e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GGT1—prostate cancer	1.76e-07	1.41e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MYC—prostate cancer	1.76e-07	1.41e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TGFB1—prostate cancer	1.75e-07	1.41e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CG—prostate cancer	1.75e-07	1.41e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—prostate cancer	1.75e-07	1.4e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—AKT1—prostate cancer	1.75e-07	1.4e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CASP3—prostate cancer	1.74e-07	1.4e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL2—prostate cancer	1.74e-07	1.4e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EGFR—prostate cancer	1.74e-07	1.4e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—AKT1—prostate cancer	1.74e-07	1.4e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KRAS—prostate cancer	1.73e-07	1.39e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NCOA1—prostate cancer	1.73e-07	1.39e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EGFR—prostate cancer	1.72e-07	1.38e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—SRC—prostate cancer	1.72e-07	1.38e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.71e-07	1.37e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KRAS—prostate cancer	1.71e-07	1.37e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCND1—prostate cancer	1.7e-07	1.36e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL6—prostate cancer	1.69e-07	1.36e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CTNNB1—prostate cancer	1.68e-07	1.35e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CB—prostate cancer	1.68e-07	1.35e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—prostate cancer	1.67e-07	1.34e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTGS2—prostate cancer	1.67e-07	1.34e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—MTHFR—prostate cancer	1.66e-07	1.34e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PIK3CA—prostate cancer	1.66e-07	1.34e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—INS—prostate cancer	1.66e-07	1.33e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—STAT3—prostate cancer	1.66e-07	1.33e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—IL6—prostate cancer	1.65e-07	1.33e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PIK3CA—prostate cancer	1.65e-07	1.33e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—AKT1—prostate cancer	1.65e-07	1.33e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—RXRA—prostate cancer	1.65e-07	1.33e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MMP9—prostate cancer	1.65e-07	1.32e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KRAS—prostate cancer	1.64e-07	1.32e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CDKN1A—prostate cancer	1.64e-07	1.32e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PTEN—prostate cancer	1.64e-07	1.32e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PPARA—prostate cancer	1.63e-07	1.31e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PIK3CA—prostate cancer	1.63e-07	1.31e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CREBBP—prostate cancer	1.62e-07	1.31e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KRAS—prostate cancer	1.62e-07	1.3e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL6—prostate cancer	1.6e-07	1.29e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PIK3CA—prostate cancer	1.59e-07	1.28e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—COMT—prostate cancer	1.59e-07	1.28e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL6—prostate cancer	1.58e-07	1.27e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTP1—prostate cancer	1.58e-07	1.27e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—prostate cancer	1.57e-07	1.27e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PIK3CA—prostate cancer	1.57e-07	1.26e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EP300—prostate cancer	1.56e-07	1.26e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AKT1—prostate cancer	1.56e-07	1.25e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ITPR1—prostate cancer	1.56e-07	1.25e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—prostate cancer	1.54e-07	1.24e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CD—prostate cancer	1.54e-07	1.24e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MYC—prostate cancer	1.54e-07	1.24e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTEN—prostate cancer	1.54e-07	1.24e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CAV1—prostate cancer	1.54e-07	1.23e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TGFB1—prostate cancer	1.54e-07	1.23e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—AKT1—prostate cancer	1.52e-07	1.22e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—prostate cancer	1.52e-07	1.22e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PIK3CA—prostate cancer	1.51e-07	1.22e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PIK3CA—prostate cancer	1.51e-07	1.21e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EGFR—prostate cancer	1.51e-07	1.21e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PIK3CA—prostate cancer	1.49e-07	1.2e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—prostate cancer	1.48e-07	1.19e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AKT1—prostate cancer	1.48e-07	1.19e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TYMS—prostate cancer	1.47e-07	1.18e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.47e-07	1.18e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—STAT3—prostate cancer	1.47e-07	1.18e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—EP300—prostate cancer	1.47e-07	1.18e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—IL6—prostate cancer	1.46e-07	1.18e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—prostate cancer	1.46e-07	1.17e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—AKT1—prostate cancer	1.46e-07	1.17e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—NOS3—prostate cancer	1.45e-07	1.17e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTM1—prostate cancer	1.45e-07	1.17e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTEN—prostate cancer	1.45e-07	1.17e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—prostate cancer	1.44e-07	1.16e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL6—prostate cancer	1.44e-07	1.16e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—LPL—prostate cancer	1.43e-07	1.15e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KRAS—prostate cancer	1.42e-07	1.14e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL6—prostate cancer	1.41e-07	1.13e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CG—prostate cancer	1.4e-07	1.12e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL6—prostate cancer	1.39e-07	1.12e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—EP300—prostate cancer	1.38e-07	1.11e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.38e-07	1.11e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ERCC2—prostate cancer	1.37e-07	1.1e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MYC—prostate cancer	1.36e-07	1.09e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TGFB1—prostate cancer	1.36e-07	1.09e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—AKT1—prostate cancer	1.36e-07	1.09e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—AKT1—prostate cancer	1.35e-07	1.08e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CB—prostate cancer	1.34e-07	1.08e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL6—prostate cancer	1.34e-07	1.08e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGFR—prostate cancer	1.33e-07	1.07e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTGS2—prostate cancer	1.33e-07	1.07e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AKT1—prostate cancer	1.33e-07	1.07e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—INS—prostate cancer	1.32e-07	1.06e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL6—prostate cancer	1.32e-07	1.06e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CA—prostate cancer	1.31e-07	1.05e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AKT1—prostate cancer	1.3e-07	1.05e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CREBBP—prostate cancer	1.3e-07	1.04e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—MTHFR—prostate cancer	1.28e-07	1.03e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AKT1—prostate cancer	1.28e-07	1.03e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—prostate cancer	1.26e-07	1.02e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PPARA—prostate cancer	1.26e-07	1.01e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KRAS—prostate cancer	1.26e-07	1.01e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—AKT1—prostate cancer	1.24e-07	9.93e-07	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AKT1—prostate cancer	1.23e-07	9.92e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CD—prostate cancer	1.23e-07	9.88e-07	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AKT1—prostate cancer	1.22e-07	9.79e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CAV1—prostate cancer	1.18e-07	9.52e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—NOS3—prostate cancer	1.16e-07	9.33e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTEN—prostate cancer	1.16e-07	9.32e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL6—prostate cancer	1.16e-07	9.29e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CA—prostate cancer	1.16e-07	9.29e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—prostate cancer	1.12e-07	8.99e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—EP300—prostate cancer	1.11e-07	8.89e-07	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CA—prostate cancer	1.08e-07	8.71e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.08e-07	8.67e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CB—prostate cancer	1.07e-07	8.61e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AKT1—prostate cancer	1.07e-07	8.57e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTGS2—prostate cancer	1.06e-07	8.53e-07	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CA—prostate cancer	1.02e-07	8.23e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL6—prostate cancer	1.02e-07	8.23e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—INS—prostate cancer	1.02e-07	8.21e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CREBBP—prostate cancer	1e-07	8.04e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CD—prostate cancer	9.49e-08	7.62e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT1—prostate cancer	9.45e-08	7.59e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTEN—prostate cancer	9.26e-08	7.44e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NOS3—prostate cancer	8.96e-08	7.2e-07	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—AKT1—prostate cancer	8.86e-08	7.12e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—EP300—prostate cancer	8.83e-08	7.1e-07	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AKT1—prostate cancer	8.37e-08	6.72e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CB—prostate cancer	8.27e-08	6.65e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS2—prostate cancer	8.19e-08	6.58e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CA—prostate cancer	8.18e-08	6.57e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTEN—prostate cancer	7.15e-08	5.74e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—EP300—prostate cancer	6.81e-08	5.48e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AKT1—prostate cancer	6.68e-08	5.37e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CA—prostate cancer	6.53e-08	5.25e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AKT1—prostate cancer	5.34e-08	4.29e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CA—prostate cancer	5.04e-08	4.05e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKT1—prostate cancer	4.12e-08	3.31e-07	CbGpPWpGaD
